An observational study in Infective Endocarditis, sponsored by First Affiliated Hospital Xi'an Jiaotong University. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-07-12.
Sponsored by First Affiliated Hospital Xi'an Jiaotong University · Observational
In this study, by establishing a clinical cohort of infective endocarditis, we observed the natural prognosis and influencing factors in the process of disease development and regression; we used multi-omics technology to understand the prognostic value of its biomarkers, and provided new ideas and evidence for the pathogenesis, clinical diagnosis and treatment of IE.
Infective endocarditis is an inflammation of the inner lining of the heart valves or ventricular walls caused by direct infection of the heart by bacteria, fungi and other microorganisms via the bloodstream route. At present, the clinical diagnosis of IE is mainly based on a combination of typical symptoms, imaging and blood culture, etc. Finding more sensitive means and more accurate indicators for early detection of IE flora distribution characteristics is of great significance for the prevention and targeted treatment of IE. Therefore, in this study, by establishing a clinical cohort of infective endocarditis, we observed the natural prognosis and influencing factors in the process of disease development and regression; we used multi-omics technology to understand the prognostic value of its biomarkers, and provided new ideas and evidence for the pathogenesis, clinical diagnosis and treatment of IE.
173 studies on the registry are indexed under Endocarditis; 57 are open to participants now.
This study's planned enrollment of 2,000 is above the median of 225 across 82 observational studies indexed under Endocarditis.
Browse Endocarditis studies →First Affiliated Hospital Xi'an Jiaotong University is the lead sponsor of 314 studies on the registry; 87 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients with clinically confirmed infective endocarditis
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients diagnosed with infective endocarditis.
Other: Observational; No Interventions were given.
Observational; No Interventions were given.
Change in the incidence of MACCE
MACCE is major adverse cardio-cerebrovascular events, including myocardial infarction, stroke, vessel revascularization and all-cause death. The MACCE will be assessed from the medical records.
Time frame: 1, 3, 6 months and 1, 2, 3, 5 years after enrollment.
Incidence of adverse thrombus complications
Adverse thrombus complications including systemic embolism, infected aneurysm, splenic abscess, etc.
Time frame: 5 years after the enrollment.
Change in the incidence of infection recurrence
Diagnosis of infective endocarditis by clinical guidelines, which will be assessed from medical records.
Time frame: 1, 3, 6 months and 1, 2, 3, 5 years after enrollment.
Change in the incidence of myocardial infarction
Myocardial infarction, diagnosed by clinical doctors, will be assessed from medical records.
Time frame: 1, 3, 6 months and 1, 2, 3, 5 years after enrollment.
Change in the incidence of stroke
Stroke, diagnosed by clinical doctors, will be assessed from medical records.
Time frame: 1, 3, 6 months and 1, 2, 3, 5 years after enrollment.
Change in the incidence of vessel revascularization
Vessel revascularization, diagnosed by clinical doctors, will be assessed from medical records.
Time frame: 1, 3, 6 months and 1, 2, 3, 5 years after enrollment.
Change in the incidence of all-cause death
All-cause death, diagnosed by clinical doctors, will be assessed from medical records.
Time frame: 1, 3, 6 months and 1, 2, 3, 5 years after enrollment.
Started May 2024 (actual). Primary completion is estimated for Dec 2028, 55 months after the start.
Of 36 observational studies under Endocarditis, half reached primary completion within 62 months of starting (the median), counting those still running; a quarter within 36. This study's planned 55 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
First Affiliated Hospital Xi'an Jiaotong University →